×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMRN – amarin corporation plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/29
07:41 am
amrn
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/10
03:22 pm
amrn
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights [Yahoo! Finance]
Medium
Report
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights [Yahoo! Finance]
1/9
07:00 am
amrn
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Medium
Report
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
1/8
07:00 am
amrn
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
High
Report
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
11/9
04:15 pm
amrn
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Low
Report
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
-14.8%
amarin corporation plc - american depositary shares
7/30/2025
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
3.2%
amarin corporation plc - american depositary shares
3/12/2025
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
-12.8%
amarin corporation plc - american depositary shares
3/12/2025
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
-9.0%
amarin corporation plc - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/8
07:05 am
amrn
Form 8-K AMARIN CORP PLC\UK For: Jan 08
High
Report
Form 8-K AMARIN CORP PLC\UK For: Jan 08
1/6
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Fishman Peter L.
Medium
Report
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Fishman Peter L.
1/6
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Keenan David Paul
Medium
Report
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Keenan David Paul
1/6
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Provoost Jonathan
Medium
Report
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Provoost Jonathan
1/6
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Ketchum Steven B
Medium
Report
Form 4 AMARIN CORP PLC\UK For: Jan 02 Filed by: Ketchum Steven B
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at Citigroup Inc from $24.00 to $6.00. They now have a "buy" rating on the stock.
25.4%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
TOP News Decliners
3/15
Amarin Takes Proactive Steps to Support Public Health Priorities
-17.6%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: